Activation of subthalamic alpha 2 noradrenergic receptors induces motor deficits as a consequence of neuronal burst firing

Neurobiology of Disease

Volumn 47, Issue 3, 2012, Pages 322-330

  Delaville, Claire ^a,b   Zapata, Jonathan ^a,b   Cardoit, Laura ^a,b   Benazzouz, Abdelhamid ^a,b,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b CNRS   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Alpha 2 adrenergic receptors; Clonidine; Norepinephrine; Parkinson's disease; Single unit microrecording; Subthalamic nucleus

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; IDAZOXAN; OXIDOPAMINE; PHENYLEPHRINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CELL FUNCTION; CELL STRUCTURE; ELECTROENCEPHALOGRAM; ENZYME ACTIVATION; LOCOMOTION; MALE; MODULATION; MOTOR DYSFUNCTION; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS;

ACTION POTENTIALS; ADRENERGIC AGENTS; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC NEURONS; ANIMALS; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; IDAZOXAN; MALE; MOTOR ACTIVITY; MOVEMENT DISORDERS; OXIDOPAMINE; RATS; RECEPTORS, ADRENERGIC, ALPHA-2; SUBTHALAMIC NUCLEUS; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 84862212331     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.05.019     Document Type: Article

References (58)

1. Antonelli T., et al. Effect of alpha-adrenoreceptors in the control of spontaneous motility and morphine withdrawal syndrome. Boll. Soc. Ital. Biol. Sper. 1991, 67:965-971.
2. Arcos D., et al. Noradrenaline increases the firing rate of a subpopulation of rat subthalamic neurones through the activation of alpha 1-adrenoceptors. Neuropharmacology 2003, 45:1070-1079.
3. Baufreton J., et al. D5 (not D1) dopamine receptors potentiate burst-firing in neurons of the subthalamic nucleus by modulating an L-type calcium conductance. J. Neurosci. 2003, 23:816-825.
4. Belujon P., et al. Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats. J. Neurosci. 2007, 27:9595-9606.
5. Benabid A.L., et al. Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: methodologic aspects and clinical criteria. Neurology 2000, 55:S40-S44.
6. Benarroch E.E. The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology 2009, 73:1699-1704.
7. Benazzouz A., et al. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur. J. Neurosci. 1993, 5:382-389.
8. Benazzouz A., et al. Intraoperative microrecordings of the subthalamic nucleus in Parkinson's disease. Mov. Disord. 2002, 17(Suppl. 3):S145-S149.
9. Bergman H., et al. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990, 249:1436-1438.
10. Bergman H., et al. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 1994, 72:507-520.
11. Bertrand E., et al. Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol. 1997, 35:80-86.
12. Bevan M.D., et al. Cellular principles underlying normal and pathological activity in the subthalamic nucleus. Curr. Opin. Neurobiol. 2006, 16:621-628.
13. Bezard E., et al. Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog. Neuropsychopharmacol. Biol. Psychiatry 1999, 23:1237-1246.
14. Boraud T., et al. Effects of l-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey. Brain Res. 1998, 787:157-160.
15. Bouali-Benazzouz R., et al. Intrapallidal injection of 6-hydroxydopamine induced changes in dopamine innervation and neuronal activity of globus pallidus. Neuroscience 2009, 164:588-596.
16. Boyajian C.L., et al. Anatomical evidence for alpha-2 adrenoceptor heterogeneity: differential autoradiographic distributions of [3H]rauwolscine and [3H]idazoxan in rat brain. J. Pharmacol. Exp. Ther. 1987, 241:1079-1091.
17. Canteras N.S., et al. Afferent connections of the subthalamic nucleus: a combined retrograde and anterograde horseradish peroxidase study in the rat. Brain Res. 1990, 513:43-59.
18. Carpenter M.B., et al. Connections of the subthalamic nucleus in the monkey. Brain Res. 1981, 224:1-29.
19. Chetrit J., et al. Involvement of Basal Ganglia network in motor disabilities induced by typical antipsychotics. PLoS One 2009, 4:e6208.
20. Chopin P., et al. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 1999, 288:798-804.
21. Ciranna L., et al. Neurotransmitter-mediated control of neuronal firing in the red nucleus of the rat: reciprocal modulation between noradrenaline and GABA. Exp. Neurol. 2000, 163:253-263.
22. Colpaert F.C. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 1987, 26:1431-1440.
23. Cragg S.J., et al. Synaptic release of dopamine in the subthalamic nucleus. Eur. J. Neurosci. 2004, 20:1788-1802.
24. Crestani C.C., et al. Both alpha1 and alpha2-adrenoceptors mediate the cardiovascular responses to noradrenaline microinjected into the bed nucleus of the stria terminal of rats. Br. J. Pharmacol. 2008, 153:583-590.
25. Delaville C., et al. Noradrenaline and Parkinson's disease. Front. Syst. Neurosci. 2011, 5:31.
26. Delaville C., et al. Emerging dysfunctions consequent to combined monoaminergic depletions in parkinsonism. Neurobiol. Dis. 2012, 45:763-773.
27. Delaville C., et al. Effects of noradrenaline and serotonin depletions on the neuronal activity of globus pallidus and substantia nigra pars reticulata in experimental parkinsonism. Neuroscience 2012, 202:424-433.
28. Di Mauro M., et al. Noradrenaline modulates neuronal responses to GABA in vestibular nuclei. Neuroscience 2008, 153:1320-1331.
29. Dulawa S.C., et al. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J. Neurosci. 1999, 19:9550-9556.
30. Ehringer H., Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin. Wochenschr. 1960, 38:1236-1239.
31. Fornai F., et al. Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr. Med. Chem. 2007, 14:2330-2334.
32. Gomez-Mancilla B., Bedard P.J. Effect of nondopaminergic drugs on l-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 1993, 16:418-427.
33. Guridi J., Obeso J.A. The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a neurosurgical dogma. Brain 2001, 124:5-19.
34. Hassani O.K., Feger J. Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: an electrophysiological and c-Fos study. Neuroscience 1999, 92:533-543.
35. Hassani O.K., et al. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 1996, 72:105-115.
36. Hutchison W.D., et al. Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann. Neurol. 1998, 44:622-628.
37. Kamisaki Y., et al. Presynaptic inhibition by clonidine of neurotransmitter amino acid release in various brain regions. Eur. J. Pharmacol. 1992, 217:57-63.
38. Kamisaki Y., et al. Presynaptic alpha 2 adrenoceptors inhibit glutamate release from rat spinal cord synaptosomes. J. Neurochem. 1993, 60:522-526.
39. Kaneoke Y., Vitek J.L. Burst and oscillation as disparate neuronal properties. J. Neurosci. Methods 1996, 68:211-223.
40. Kitai S.T., Deniau J.M. Cortical inputs to the subthalamus: intracellular analysis. Brain Res. 1981, 214:411-415.
41. Lakhlani P.P., et al. Genetic evidence for involvement of multiple effector systems in alpha 2A-adrenergic receptor inhibition of stimulus-secretion coupling. Mol. Pharmacol. 1996, 50:96-103.
42. Langer S.Z. Presynaptic regulation of catecholamine release. Biochem. Pharmacol. 1974, 23:1793-1800.
43. Mathe J.M., et al. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 1996, 309:1-11.
44. Mavridis M., et al. Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats by alpha 1 as compared to alpha 2 agonists and antagonists. Brain Res. 1991, 562:216-224.
45. McCormick D.A., Wang Z. Serotonin and noradrenaline excite GABAergic neurones of the guinea-pig and cat nucleus reticularis thalami. J. Physiol. 1991, 442:235-255.
46. McCormick D.A., et al. Actions of norepinephrine in the cerebral cortex and thalamus: implications for function of the central noradrenergic system. Prog. Brain Res. 1991, 88:293-305.
47. Ni Z.G., et al. Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats. Brain Res. 2001, 899:142-147.
48. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res. Brain Res. Rev. 1995, 20:128-154.
49. Parr-Brownlie L.C., et al. Dopamine lesion-induced changes in subthalamic nucleus activity are not associated with alterations in firing rate or pattern in layer V neurons of the anterior cingulate cortex in anesthetized rats. Eur. J. Neurosci. 2007, 26:1925-1939.
50. Paxinos G., Watson C. The Rat Brain in Stereotatic Coordinates 1996, Academic Press, San Diego.
51. Stanford I.M., et al. 5-Hydroxytryptamine induced excitation and inhibition in the subthalamic nucleus: action at 5-HT(2C), 5-HT(4) and 5-HT(1A) receptors. Neuropharmacology 2005, 49:1228-1234.
52. Starke K. Influence of extracellular noradrenaline on the stimulation-evoked secretion of noradrenaline from sympathetic nerves: evidence for an -receptor-mediated feed-back inhibition of noradrenaline release. Naunyn Schmiedebergs Arch. Pharmacol. 1972, 275:11-23.
53. Swanson L.W., Hartman B.K. The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J. Comp. Neurol. 1975, 163:467-505.
54. Tai C.H., et al. Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia nigra reticulata. FASEB J. 2003, 17:1820-1830.
55. Wang R., et al. Expression of alpha 2-adrenergic receptor subtypes in the mouse brain: evaluation of spatial and temporal information imparted by 3 kb of 5' regulatory sequence for the alpha 2A AR-receptor gene in transgenic animals. Neuroscience 1996, 74:199-218.
56. Wellman P.J., Davies B.T. Effects of the alpha 1-adrenergic agonist cirazoline on locomotion and brown adipose tissue thermogenesis in the rat. Life Sci. 1992, 50:1745-1753.
57. Xiang Z., et al. Modulation of spontaneous firing in rat subthalamic neurons by 5-HT receptor subtypes. J. Neurophysiol. 2005, 93:1145-1157.
58. Yavich L., et al. Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of l-DOPA on evoked dopamine release in rat striatum. Eur. J. Pharmacol. 2003, 462:83-89.